BPC-157 is the most-studied healing peptide in the world — 544 studies and counting. Paired with TB-500 for the canonical healing stack. Here's the full protocol library plus the adjuncts worth knowing.
Compounds with the strongest trial data. Each card links to the full research deep-dive.
Pentadecapeptide from gastric juice. Angiogenesis + nitric-oxide pathway + growth factor upregulation. 544-study systematic review, no lethal or toxic dose in animals.
Actin-binding peptide that accelerates cell migration into damaged tissue. The other half of the classic healing stack — mechanism distinct from BPC-157 (cell movement vs vasculature).
The canonical healing protocol. Complementary mechanisms (angiogenesis + cell migration), documented in user reports for tendon/ligament/muscle recovery. Standard 8-12 week cycle.
Newer arginate-salt formulation of BPC-157 with improved stability. Pharmacokinetic profile differs slightly; same mechanism family. Growing use among clinicians post-Peptide-Sciences shutdown.
544-study safety review. No lethal dose in animals, but human data thin. Drug interactions, contraindications, and the cancer-angiogenesis theoretical question.
Targeted BPC-157 protocols for back pain, knee pain, and shoulder recovery. Site-specific injection strategies where evidence supports.
The BPC-157 + TB-500 + GHK-Cu combo popularized in functional-medicine circles. Full protocol with dosing and timing.
Read more →Multiple recovery-focused stack options comparing mechanism overlap, duration, and cost. Pick the right one for your injury type.
Read more →Head-to-head: mechanism differences, use cases, and when to run one vs the other vs both.
Read more →BPC-157 has the deepest research base (544+ studies) and the best animal safety profile. For most soft-tissue injuries, BPC-157 alone is a reasonable starting point. For complex or stubborn injuries, the BPC-157 + TB-500 stack is the most-used combination in user communities.
User reports typically see subjective improvement in 1-2 weeks for acute injuries, 4-8 weeks for chronic tendon/ligament issues. Animal studies show measurable histological changes at similar timescales. 8-12 weeks is the standard cycle length.
Subcutaneous injection near the injury site is common in user protocols and is mechanistically reasonable (higher local concentration). Some clinicians do intra-articular injections for joint-specific issues. Standard SC injection works fine for systemic effect.
Long-term (>12 weeks continuous) human safety data is thin. The theoretical concern is angiogenesis — new blood vessel growth could theoretically accelerate cancer in at-risk individuals. Most users cycle 8-12 weeks on, take a break.
Swiss Chems stocks third-party HPLC-tested peptides with published COAs per batch. HighPeptides' primary vendor reference.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
13 related research pages covering specific questions, compounds, and edge cases.
BPC-157 and TB-500 are not FDA-approved for human use. They're sold for research purposes. The healing effects described are documented in animal studies and user reports, not confirmed by large human trials.
Not medical advice. Always consult a qualified healthcare provider. Research use only.